Increased myostatin levels also contribute to the development of sarcopenia, especially in the elderly, in people with cancer, in patients with sepsis, in patients treated in intensive care units, and in patients with chronic obstructive pulmonary disease. Here, MSTN is linked to chronic obstructive pulmonary disease.